{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T04:53:30Z","timestamp":1787892810833,"version":"build-2784847793"},"reference-count":91,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am Soc Clin Oncol Educ Book"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:p>Neoadjuvant systemic therapy has emerged as a strategy to improve outcomes in high-risk localized genitourinary malignancies. In bladder cancer, neoadjuvant cisplatin-based chemotherapy with or without immunotherapy is standard of care, with pathologic complete response (pCR) serving as a validated surrogate for survival after chemotherapy and a promising potential surrogate for survival after other neoadjuvant treatments like immunotherapy. Enfortumab vedotin and immune checkpoint inhibitors have expanded treatment options, with ongoing studies evaluating novel adjuvant approaches tailored to patients' postoperative circulating tumor DNA. In renal cell carcinoma (RCC), the field is nascent, no approved neoadjuvant regimens exist, and treatment outside clinical trials is not recommended. Early trials of tyrosine kinase inhibitor monotherapy showed limited pathologic responses, while immune checkpoint inhibitor-based combinations have demonstrated feasibility, safety, and the capacity to induce pathologic responses including pCR. Critical gaps remain in both diseases. In RCC, standardized pathologic response criteria are lacking, and surrogacy between pathologic end points and long-term outcomes has not been established. In bladder cancer, optimal post-pCR management and integration of novel agents require further study. Emerging technologies, particularly artificial intelligence (AI)\u2013driven digital pathology, offer potential to enhance diagnosis, refine prognostic stratification, and predict treatment response, although prospective validation across diverse populations is needed. This chapter examines neoadjuvant therapy and pathologic response assessment in RCC and bladder cancer, explores pathologic biomarker development including AI applications, and highlights future directions to optimize therapeutic sequencing and outcomes.<\/jats:p>","DOI":"10.1200\/edbk-26-516902","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T20:59:27Z","timestamp":1772571567000},"source":"Crossref","is-referenced-by-count":2,"title":["Neoadjuvant Systemic Therapy in Kidney and Bladder Cancer: Current Evidence and Emerging Paradigms"],"prefix":"10.1200","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0581-7963","authenticated-orcid":true,"given":"Rana R.","family":"McKay","sequence":"first","affiliation":[{"name":"Moores Cancer Center, University of California San Diego, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asha","family":"Tipirneni","sequence":"additional","affiliation":[{"name":"James P. Wilmot Cancer Institute, University of Rochester, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rick","family":"Bangs","sequence":"additional","affiliation":[{"name":"Bladder Cancer Advocacy Network, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan J.","family":"Guercio","sequence":"additional","affiliation":[{"name":"James P. Wilmot Cancer Institute, University of Rochester, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2024.09.002"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211437"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"S882","DOI":"10.1016\/j.annonc.2025.08.2229","article-title":"1601O 3-year survival with neoadjuvant-adjuvant pembrolizumab from SWOG S1801","volume":"36","author":"Patel SP","year":"2025","unstructured":"Patel SP, Othus M, Prieto V, et al: 1601O 3-year survival with neoadjuvant-adjuvant pembrolizumab from SWOG S1801. Ann Oncol 36:S882-S883, 2025","journal-title":"Ann Oncol"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0198-0"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.09.069"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2017.07.015"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.7759"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.01.035"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2015.03.096"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2010.09357.x"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2014.11.009"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-025-00922-5"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2021.04.002"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00211-0"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.09.112"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.6_suppl.289"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2019-0111"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.4509"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38342-7"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008475"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.5_suppl.555"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30332-8"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-01188-3"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01851-x"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30151-2"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00345-6"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad166"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2025.01.007"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2106391"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02574-0"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01658-0"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.09.110"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2408154"},{"key":"e_1_3_2_36_2","volume-title":"LBA2\u2014Perioperative (Periop) Enfortumab Vedotin (EV) plus Pembrolizumab (Pembro) in Participants (Pts) with muscle-invasive Bladder Cancer (MIBC) Who Are cisplatin-ineligible: The Phase III KEYNOTE-905 Study","author":"Vulsteke C","year":"2025","unstructured":"Vulsteke C, Kaimakliotis H, Danchaivijitr P, et al: LBA2\u2014Perioperative (Periop) Enfortumab Vedotin (EV) plus Pembrolizumab (Pembro) in Participants (Pts) with muscle-invasive Bladder Cancer (MIBC) Who Are cisplatin-ineligible: The Phase III KEYNOTE-905 Study. Berlin, Germany, ESMO, 2025"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02051"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.10.026"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0628-7"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022148"},{"key":"e_1_3_2_41_2","volume-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Bladder Cancer, Version 3.2025","author":"Flaig TW","year":"2025","unstructured":"Flaig TW, Spiess PE, Abern M, et al: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Bladder Cancer, Version 3.2025. 2025"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00587-9"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.08.024"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.4785"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.2465"},{"key":"e_1_3_2_46_2","volume-title":"Pfizer: PADCEV\u2122 plus Keytruda\u00ae Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility","year":"2025","unstructured":"Pfizer: PADCEV\u2122 plus Keytruda\u00ae Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility. 2025. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/padcevtm-plus-keytrudar-significantly-improves-survival"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS588"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS579"},{"key":"e_1_3_2_49_2","article-title":"Efficacy and safety of disitamab vedotin combined with gemcitabine as neoadjuvant therapy in muscle-invasive bladder cancer: An open-label, multicenter, single-arm, phase 2 trial","author":"Huang H","unstructured":"Huang H, Ma W, Zeng X, et al: Efficacy and safety of disitamab vedotin combined with gemcitabine as neoadjuvant therapy in muscle-invasive bladder cancer: An open-label, multicenter, single-arm, phase 2 trial. Eur Urol 10.1016\/j.eururo.2025.10.009 [epub ahead of print on November 4, 2025]","journal-title":"Eur Urol"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.5_suppl.665"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.4591"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.4518"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.4595"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.04.013"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.06.049"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01148"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.6_suppl.TPS599"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02568-1"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01214"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.5_suppl.815"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS4615"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000001602"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-01608"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-012-1249-4"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034442"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401726"},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.09.139"},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.04.005"},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.5_suppl.659"},{"key":"e_1_3_2_70_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02052"},{"key":"e_1_3_2_71_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-1860"},{"key":"e_1_3_2_72_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03642-9"},{"key":"e_1_3_2_73_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511885"},{"key":"e_1_3_2_74_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2025-CT101"},{"key":"e_1_3_2_75_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.4503"},{"key":"e_1_3_2_76_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.4589"},{"key":"e_1_3_2_77_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242316578"},{"key":"e_1_3_2_78_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14235807"},{"key":"e_1_3_2_79_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15184518"},{"key":"e_1_3_2_80_2","first-page":"192","article-title":"Predicting response to intravesical bacillus calmette-guerin in high-risk nonmuscle-invasive bladder cancer using an artificial intelligence-powered pathology assay: Development and validation in an International 12-Center Cohort","volume":"213","author":"Lotan Y","year":"2025","unstructured":"Lotan Y, Krishna V, Abuzeid WM, et al: Predicting response to intravesical bacillus calmette-guerin in high-risk nonmuscle-invasive bladder cancer using an artificial intelligence-powered pathology assay: Development and validation in an International 12-Center Cohort. J Urol 213:192-204, 2025","journal-title":"J Urol"},{"key":"e_1_3_2_81_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2020.12.008"},{"key":"e_1_3_2_82_2","article-title":"Multiresolution application of artificial intelligence in digital pathology for prediction of positive lymph nodes from primary tumors in bladder cancer","author":"Harmon SA","unstructured":"Harmon SA, Sanford TH, Brown GT, et al: Multiresolution application of artificial intelligence in digital pathology for prediction of positive lymph nodes from primary tumors in bladder cancer. JCO Clin Cancer Inform 10.1200\/CCI.19.00155","journal-title":"JCO Clin Cancer Inform"},{"key":"e_1_3_2_83_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1516264"},{"key":"e_1_3_2_84_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2024.05.012"},{"key":"e_1_3_2_85_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-025-02034-x"},{"key":"e_1_3_2_86_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-025-01560-y"},{"key":"e_1_3_2_87_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100382"},{"key":"e_1_3_2_88_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00363"},{"key":"e_1_3_2_89_2","doi-asserted-by":"crossref","unstructured":"Gupta S Sonpavde G Weight CJ et al. Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab gemcitabine and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy. J Clin Oncol 38:439-439 2020","DOI":"10.1200\/JCO.2020.38.6_suppl.439"},{"key":"e_1_3_2_90_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01485"},{"key":"e_1_3_2_91_2","doi-asserted-by":"crossref","unstructured":"Kaimakliotis HZ Adra N Kelly WK et al. Phase II neoadjuvant gemcitabine and pembrolizumab for locally advanced urothelial cancer: Interim results from the cisplatin-ineligible cohort of GU14-188. J Clin Oncol 38:5019 2020 (suppl 15)","DOI":"10.1200\/JCO.2020.38.15_suppl.5019"},{"key":"e_1_3_2_92_2","doi-asserted-by":"crossref","unstructured":"Guercio BJ Pietzak EJ Brown S et al. Neoadjuvant nivolumab (N) +\/- ipilimumab (I) in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC). J Clin Oncol 40:498-498 2022","DOI":"10.1200\/JCO.2022.40.6_suppl.498"}],"container-title":["American Society of Clinical Oncology Educational Book"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/EDBK-26-516902","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T20:59:30Z","timestamp":1772571570000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/EDBK-26-516902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":91,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1200\/EDBK-26-516902"],"URL":"https:\/\/doi.org\/10.1200\/edbk-26-516902","relation":{},"ISSN":["1548-8748","1548-8756"],"issn-type":[{"value":"1548-8748","type":"print"},{"value":"1548-8756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"article-number":"e516902"}}